2015
DOI: 10.1093/jac/dku538
|View full text |Cite
|
Sign up to set email alerts
|

NOTA: a potent metallo-β-lactamase inhibitor

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
49
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 56 publications
(50 citation statements)
references
References 11 publications
1
49
0
Order By: Relevance
“…The choice of isolates used in this study was based on our previous report where NOTA was described to inhibit MBL‐producing CREs but not CREs producing the serine‐based carbapenemases (Somboro et al . ). The ability of metal chelators to complex zinc in the active site of the MBL enzyme deactivates the hydrolysis of carbapenems.…”
Section: Discussionmentioning
confidence: 97%
See 3 more Smart Citations
“…The choice of isolates used in this study was based on our previous report where NOTA was described to inhibit MBL‐producing CREs but not CREs producing the serine‐based carbapenemases (Somboro et al . ). The ability of metal chelators to complex zinc in the active site of the MBL enzyme deactivates the hydrolysis of carbapenems.…”
Section: Discussionmentioning
confidence: 97%
“…While NOTA worked better in our previous studies, we must consider that its extremely polar and therefore does not share similar physico‐chemical properties of the drugs that it needs to combine with, that is, carbapenems (Somboro et al . ). These results would and always be limited to in vitro work; so to modify its pharmacological properties, NODAGA was derivatized with peptides containing N ‐methylated amino acids.…”
Section: Discussionmentioning
confidence: 97%
See 2 more Smart Citations
“…To date, severalc hemical familiesh ave been reported to inhibit MBLs. They include biphenyltetrazoles, [14] various thiol-and thioester-containing compounds, [15][16][17][18][19][20][21][22][23][24][25][26][27] di- [28][29][30][31] and polycarboxylate compounds, [32][33][34] hydroxamates, [35] arylsulfonyl-containingc ompounds, [36][37][38][39][40] trifluoromethyl alcohols and ketones, [41] tricyclic natural compounds, [42] and cyclic boronates. [43] Approaches to covalent MBL inhibitors have also been considered.…”
Section: Introductionmentioning
confidence: 99%